CLINICAL CASE HISTORY OF EPTIFIBATIDE USE DURING CORONARY INTERVENTION IN PATIENT WITH CORONARY FAILURE
| Autor: | T. S. Kireeva, K. A. Kireev, A. V. Krasnopeev |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
lcsh:Diseases of the circulatory (Cardiovascular) system
medicine.medical_specialty Antiplatelet drug medicine.medical_treatment RM1-950 чрескожное коронарное вмешательство Internal medicine medicine Diseases of the circulatory (Cardiovascular) system Pharmacology (medical) cardiovascular diseases Medical prescription эптифибатид eptifibatide stent thrombosis острая коронарная патология business.industry percutaneous coronary intervention lcsh:RM1-950 Percutaneous coronary intervention Heparin equipment and supplies medicine.disease Clopidogrel Thrombosis Surgery lcsh:Therapeutics. Pharmacology surgical procedures operative medicine.anatomical_structure lcsh:RC666-701 RC666-701 тромбоз стента coronary failure Eptifibatide Cardiology Therapeutics. Pharmacology Cardiology and Cardiovascular Medicine business medicine.drug Artery |
| Zdroj: | Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 11, Iss 2, Pp 159-164 (2015) |
| ISSN: | 2225-3653 1819-6446 |
| DOI: | 10.20996/1819-6446-2015-11-2-159-164 |
| Popis: | Clinical case history of endovascular intervention in infarct related coronary artery with 4 sirolimus-eluting stents implantation and their further thrombosis during early postoperative period is described. Percutaneous coronary intervention was successful after the balanced medication with 2 antiplatelet drugs (acetylsalicylic acid and clopidogrel) and heparin. There were not any reasons for additional prescription of antiplatelet medicine. It seems that one of the main reasons of the stent thrombosis was the extended area of 4 sirolimus-eluting stents implantation into the affected vessel. After the analysis of our clinical case history we propose that for stent thrombosis prevention in multistent (≥4 drugeluting stents) interventions it is necessary to apply additional antiplatelet drug – glycoprotein IIb/IIIa inhibitor eptifibatide. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|